Fig. 7: Immune cell components in tumour and normal samples, by clinical parameters.
From: Evidence of DNA methylation heterogeneity and epipolymorphism in kidney cancer tissue samples
Boxplots depicting the LMC1 (latent methylation component 1) content obtained from methylation deconvolution analysis. LMC1 content is shown in ccRCC vs normal kidney (A). The LMC1 component in tumour samples is also shown by grade, stage, Leibovich score and recurrence status (B). Boxplots depicting the immune score obtained from RNA-seq analysis (using ‘ESTIMATE’) for tumour vs normal samples (C). The immune score is shown in tumour samples, by grade and stage (D) and by patient (E). Results of immune cell decomposition from RNA-seq analysis (using ‘CIBERTSORTx’), for each patient (F), and in tumour versus normal samples (G). * = p value < 0.05; ** = p value < 0.01, *** = p value < 0.001, **** = p value < 0.0001.
